S&P Futures
5,951.50 +12.75 (+0.21%) Dow Futures
43,538.00 +138.00 (+0.32%) Nasdaq Futures
20,818.75 +51.00 (+0.25%) Russell 2000 Futures
2,333.80 -0.30 (-0.01%) Crude Oil
70.10 +0.71 (+1.02%) Gold
2,638.20 +7.20 (+0.27%)
Autonomix Medical, Inc. (AMIX)
Pre-Market:
| Previous Close | 12.39 |
| Open | 13.00 |
| Bid | 9.74 x 200 |
| Ask | 15.27 x 200 |
| Day's Range | 11.72 - 13.65 |
| 52 Week Range | 7.51 - 152.00 |
| Volume | |
| Avg. Volume | 494,857 |
| Market Cap | 15.197M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -19.74 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.00 |
GlobeNewswireAutonomix Medical, Inc. Reports Second Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update
Ongoing proof-of-concept (PoC) clinical trial in pain associated with pancreatic cancer; Preliminary results demonstrate 100% of the lead-in patient responder group went to zero opioid use at 4-6 weeks post-procedure Company’s first-in-class technology has demonstrated significant, enduring reduction in pain and improvement in quality of life in ongoing PoC study to date THE WOODLANDS, TX, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a
GlobeNewswireAutonomix Medical, Inc. Reports New Positive Topline Results from First 15 Patients’ 7-Day Data Highlighting Significant Impact on Treatment of Pancreatic Cancer Pain with Maintained Pain Reduction
Autonomix Medical, Inc Summary of First 15 Patients’ Topline Results 7-Days Post-Procedure Autonomix Medical, Inc Pain Scale 79% responder rate achieved with zero opioid use and quality of life improvement at 7 days post-procedure Company reaches 60% enrollment with 15 patients1 successfully enrolled; No unexpected complications or procedural-related significant adverse events Clinically meaningful mean of 4.96 or 63% reduction of pain on the VAS pain scale was observed THE WOODLANDS, TX, Oct. 3
